Lurbinectedin: an FDA-approved inducer of immunogenic cell death for the treatment of small-cell lung cancer

Lurbinectedin is a DNA-binding inhibitor of transcription that potently induces immunogenic cell death (ICD). In June 2020, the Federal Drug Administration (FDA) approved lurbinectedin for the salvage treatment of small-cell lung cancer that has relapsed from platinum compound-based first-line chemo...

Descripción completa

Detalles Bibliográficos
Autores principales: Kepp, Oliver, Zitvogel, Laurence, Kroemer, Guido
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7458590/
https://www.ncbi.nlm.nih.gov/pubmed/32923159
http://dx.doi.org/10.1080/2162402X.2020.1795995

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7458590/
https://www.ncbi.nlm.nih.gov/pubmed/32923159
http://dx.doi.org/10.1080/2162402X.2020.1795995

Ejemplares similares